Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRL-101
- Development stage
- Phase 2
- Lead developer
- BRL Medicine
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
BRL-101 is an autologous, genetically modified hematopoietic stem cell gene therapy developed by BRL Medicine for the treatment of transfusion-dependent beta-thalassemia (TDT) and sickle cell disease. The therapy uses CRISPR/Cas9 gene editing to disrupt the erythroid-specific enhancer region of the BCL11A gene in CD34+ hematopoietic stem and progenitor cells. This disruption reduces BCL11A expression, leading to increased production of fetal hemoglobin (HbF), which can compensate for defective or absent adult hemoglobin in patients with beta-thalassemia or sickle cell disease. The edited cells are reinfused into the patient after myeloablation, where they engraft and repopulate the blood system with corrected cells. Clinical trials have shown that BRL-101 can induce transfusion independence in TDT patients and increase total hemoglobin and HbF levels[1][3][6]. The product is based on BRL Medicine’s ModiHSC platform.
- Other names
- Autologous Hematopoietic Stem Cells (BRL Medicine)
Beyond the preview
Go deeper on BRL-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRL-101.